Argenx Gets Health Canada Approval for CIDP Treatment Vyvgart SC

MT Newswires Live11-06

Argenx (ARGX) said Wednesday that Health Canada approved Vyvgart SC as a standalone treatment for adults with active chronic inflammatory demyelinating polyneuropathy, or CIDP.

The authorization was supported by results from the global Adhere study, where 69% of patients showed improvement and the risk of relapse fell 61% versus placebo. Safety findings were consistent with previous studies, the company said.

Vyvgart Sc, administered once weekly via a prefilled syringe, is the first and only Fc receptor blocker approved in Canada for CIDP. It can be self-administered or given by a caregiver, offering greater flexibility for patients, according to the company.

Price: 829.25, Change: -2.23, Percent Change: -0.27

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581775357?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581775357","market":"hk","top_or_hot":-1,"title":"Argenx Gets Health Canada Approval for CIDP Treatment Vyvgart SC","media":"MT Newswires Live","content":"<html><body><p> Argenx (ARGX) said Wednesday that Health Canada approved Vyvgart SC as a standalone treatment for adults with active chronic inflammatory demyelinating polyneuropathy, or CIDP.</p><p>The authorization was supported by results from the global Adhere study, where 69% of patients showed improvement and the risk of relapse fell 61% versus placebo. Safety findings were consistent with previous studies, the company said.</p><p>Vyvgart Sc, administered once weekly via a prefilled syringe, is the first and only Fc receptor blocker approved in Canada for CIDP. It can be self-administered or given by a caregiver, offering greater flexibility for patients, according to the company.</p><p>Price: 829.25, Change: -2.23, Percent Change: -0.27</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenx Gets Health Canada Approval for CIDP Treatment Vyvgart SC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenx Gets Health Canada Approval for CIDP Treatment Vyvgart SC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-06 00:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Argenx (ARGX) said Wednesday that Health Canada approved Vyvgart SC as a standalone treatment for adults with active chronic inflammatory demyelinating polyneuropathy, or CIDP.</p><p>The authorization was supported by results from the global Adhere study, where 69% of patients showed improvement and the risk of relapse fell 61% versus placebo. Safety findings were consistent with previous studies, the company said.</p><p>Vyvgart Sc, administered once weekly via a prefilled syringe, is the first and only Fc receptor blocker approved in Canada for CIDP. It can be self-administered or given by a caregiver, offering greater flexibility for patients, according to the company.</p><p>Price: 829.25, Change: -2.23, Percent Change: -0.27</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2581775357","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581775357","pubTimestamp":1762361860,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Argenx  said Wednesday that Health Canada approved Vyvgart SC as a standalone treatment for adults with active chronic inflammatory demyelinating polyneuropathy, or CIDP.The authorization was supported by results from the global Adhere study, where 69% of patients showed improvement and the risk of relapse fell 61% versus placebo. Safety findings were consistent with previous studies, the company said.Vyvgart Sc, administered once weekly via a prefilled syringe, is the first and only Fc receptor blocker approved in Canada for CIDP. It can be self-administered or given by a caregiver, offering greater flexibility for patients, according to the company.Price: 829.25, Change: -2.23, Percent Change: -0.27","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ARGX":"Argenx SE","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"Argenx获得加拿大卫生部批准用于CIDP治疗Vyvgart SC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"Argenx (ARGX) said Wednesday that Health Canada approved Vyvgart SC as a standalone treatment for adults with active chronic inflammatory demyelinating polyneuropathy, or CIDP.The authorization was supported by results from the global Adhere study, where 69% of patients showed improvement and the risk of relapse fell 61% versus placebo. Safety findings were consistent with previous studies, the company said.Vyvgart Sc, administered once weekly via a prefilled syringe, is the first and only Fc receptor blocker approved in Canada for CIDP. It can be self-administered or given by a caregiver, offering greater flexibility for patients, according to the company.Price: 829.25, Change: -2.23, Percent Change: -0.27","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581775357","isCrawlerRequest":true}